Light-Controlled Biomanufacturing: The Next Paradigm Shift for Complex Biologics

Session details:

As biologics pipelines grow more complex and cost pressure rises, Deniz Kent, PhD, will explain why light — programmable, precise, and digitally native — is ready to become the biomanufacturing industry’s defining control modality. Drawing on Prolific’s work with challenging pipeline candidates, he will show how optogenetic control is already supporting asset owners and CDMOs in bringing high-performance therapies to patients faster, more reliably, and at lower cost, while integrating seamlessly with existing platforms and bioreactor infrastructure.